Objective: S100A4 is a Ca-binding protein that regulates cell growth, survival, and motility. The abundant expression of S100A4 in rheumatiod arthritis contributes to the invasive growth of joint tissue and to bone damage. In the present study, we analysed the role of S100A4 in bone homeostasis. Methods: Peripheral quantitative computed tomography and histomorphometric analysis were performed in mice lacking the entire S100A4 protein (S100A4KO) and in wild-type (WT) counterparts treated with shRNA-lentiviral constructs targeting S100A4 (S100A4-shRNA). Control groups consisted of sex-matched WT counterparts and WT mice treated with a non-targeting RNA construct. Results: S100A4 deficiency was associated with higher trabecular and cortical bone mass, increased number and thickness of trabeculi combined with larger periosteal circumference and higher predicted bone strength. S100A4 inhibition by shRNA led to an increase in cortical bone in WT mice. S100A4-deficieny was associated with a reduced number of functional osteoclasts. S100A4KO and S100A4-shRNA-treated bone marrow progenitors gave rise to a large number of small TRAP+ cells with few nuclei and few pseudopodial processes. Poor osteoclastogenesis and the low resorptive capacity in S100A4Ko mice may be linked to low levels of surface integrins, impaired adhesion capacity, and poor multinucleation in S100A4-deficient osteoclasts, as well as a low content of proteolytic enzymes cathepsin K and MMP3 and MMP9 to break down the organic matrix. Conclusion: S100A4 emerges as a negative regulator of bone metabolism potentially responsible for the excessive bone turnover in conditions marked by high levels of S100A4 protein, such as inflammation and rheumatoid arthritis.
Introduction
S100A4, a 101-amino-acid protein, is a member of the S100 family of calcium-binding proteins [1, 2] . S100A4 has initially attracted attention as a metastasis promoting protein, being later reported in connection with pulmonary disease, kidney and liver fibrosis, arthritis and neuronal injuries. Under physiological conditions, S100A4 is required for cell motility, cell differentiation, and tissue remodelling. It is expressed in the cells with a mobile phenotype, such as endothelial cells, fibroblasts and leukocytes [1] . Additionally, high expression levels of S100A4 are observed during cell differentiation, in mesenchymal bone marrow cells, and in angiogenesis and organogenesis.
Similarly to other members of the S100 family, the functions of S100A4 are mediated through the interaction of the protein with its binding partners. S100A4 directly interacts with cytoskeletal proteins, such as actin, tropomyosin, and non-muscle myosin, and participates in cytoskeletal rearrangements, cell shape changes, and motility. For example, S100A4 binds tropomyosin and non-muscle myosin II in a Ca 2+ -dependent manner to inhibit the actin-regulated ATPase activity of myosin II [3, 4] . The binding of S100A4 to non-muscle myosin promotes the disassembly of myosin filaments [3, 5] and, in the presence of chemoattractants, enhances cell polarisation as well as directed migration. S100A4 is located at the leading edge of migrating cells, where it induces the formation of flexible protrusions [6] . S100A4 interacts with transcription factors p53, p37, methionine aminopeptidase 2, and serpins (e.g., matrix metalloproteinases and urokinase) [2] . Binding of S100A4 to these transcription factors can lead to activation as well as inhibition of their function. In addition, extracellular S100A4 is a potent inducer of chemokines, metalloproteinases and urokinases [7] [8] [9] . These effects of S100A4 are mediated, at least in part, through binding to the receptor of advanced glycation end products (RAGE) and activating the NF-kB signalling pathway. Interaction between S100A4 and transitory annexin II exposed on the extracellular membrane surface is proposed as a potential RAGE-independent mechanism of cell activation [10] .
Rheumatoid arthritis (RA) is characterised by synovial hyperplasia caused by proliferating synovial lining cells and by an accumulation of inflammatory cells such as macrophages and T and B lymphocytes. Synovial hyperplasia contributes to the progressive destruction of joint cartilage and underlying subarticular bone in RA. Increased expression of S100A4 has been recently found in rheumatoid synovial fibroblasts and synovial tissues from RA patients [11, 12] . Compared to the expression of other S100 proteins such as S100A7, S100A8/ S100A9 and S100A12, S100A4 expression is predominant in rheumatoid synovial tissues. Importantly, plasma and synovial fluid of RA patients contain S100A4 in a bioactive oligomeric conformation [13] . The molecular role of S100A4 in the pathogenesis of RA is thought to be linked to the regulation of cell motility, adhesion, apoptosis, and proliferation, the properties that promote cancer and metastasis [14] . Consistent with this hypothesis, high levels of S100A4 in RA patients are associated with expression of other tumour-related proteins, survivin and Flt3-ligand, which have an established role in the pathogenesis of RA [15] . It is hypothesised that circulating S100A4 modulates target cells towards a more aggressive phenotype, particularly by promoting the production of proteolytic enzymes and matrix metalloproteinases, which are required for matrix degradation and joint destruction characteristic of severe RA. Indeed, S100A4 levels directly correlate to persistent disease and to progressive bone destruction inside inflamed joints [15] . A regression analysis indicated high levels of S100A4 as a sensitive predictive parameter of radiographic joint damage in RA. Additionally, S100A4-deficient mice are protected from subarticular bone destruction and from the systemic loss of bone mineral content during septic arthritis [16] . The present study further assesses the role of S100A4 in the regulation of bone mass in vivo.
Bone formation is a result of the collaborative activities of two major cell types: osteoblasts and osteoclasts [17] [18] [19] . Bone undergoes continuous remodelling. Osteoblasts produce proteins of the extracellular collagenous matrix, such as bone sialoprotein and type I collagen, which are later mineralised under the control of osteocalcin and osteopontin by the deposition of hydroxyapatite crystals. Osteoblast formation is controlled by a combination of cytokines and hormones, of which insulin-like growth factors and Wnt proteins/low-density lipoprotein receptor-related protein 5 (LRP5) seem to be of major importance. Osteoclasts break down mineralised extracellular collagenous matrix, resorbing old bone and permitting its replacement with new bone. The differentiation of mononuclear osteoclast precursors into multinuclear mature osteoclasts is regulated by M-CSF, which stimulates osteoclast precursor proliferation and induces the expression of RANK and the ligand of the receptor activator of nuclear factor-kB (RANKL) [17] . RANKL availability is regulated by osteoprotegerin (OPG), which functions as a soluble decoy receptor. Osteoclast maturation leads to its tight attachment to the surface of bone and to the formation of a sealing zone marked by an F-actin ring and a ruffled border, which are essential for the extracellular resorption of the mineral matrix [17, 18] . The attachment and ruffled border formation requires expression of matrix osteopontin (OPN), and integrins, located in the podosomes of osteoclasts. The most prominent integrins expressed by mature osteoclasts are the α 1 β 2 (CD49/CD18) and α v β 3 (CD51/CD61) heterodimers. Acidification of the osteoclast sealing zone and the concomitant release of proteolytic enzymes, especially the cysteine protease, cathepsin K, and matrix metalloproteinases (MMPs), are crucial for breaking down the organic matrix [19] .
The underlying mechanisms for the role of S100A4 in bone remodelling have recently been proposed [20, 21] . The transcription of S100A4 is regulated by the canonical Wnt/β-catenin pathway [22, 23] , which is the major mechanism controlling the formation of osteoblasts. S100A4 is also an essential mediator of Wnt-LPR5/ 6-β-catenin signalling effects [22] . Mesenchymal cells committed to osteoblast differentiation express high levels of S100A4 mRNA, which is undetectable in mature osteoblasts and osteocytes after the formation of a mineralised matrix. Expression of S100A4 is associated with the inhibition of mineralisation, while intracellular inhibition of S100A4 in a mouse osteoblastic cell line increases activation of the transcription factors Runx2 and Osterix [21] and the expression of bone sialoprotein and osteocalcin which are essential proteins of mature osteoblasts [7, 20] . Several observations argue for the role of S100A4 in osteoclast formation and bone resorption. Firstly, intracellular interaction between S100A4 and liprin-β1 [4] potentiates the expression of integrins α v and α 5 [24, 25] , the most prominent integrins expressed by mature osteoclasts. Integrins promote osteoclast survival and cytoskeletal remodelling during matrix adhesion [2] . Secondly, extracellular S100A4 up-regulates the production of OPN [7] , a matrix protein required for the attachment and ruffled border formation of osteoclasts. In addition, cross talk between the S100A4/RAGE complex and bone matrix protein 2 signalling regulates the expression of intracellular chloride channels 4 [26] , which are essential for the acidification of the resorptive cavity of osteoclasts. Finally, S100A4 regulates the synthesis of MMPs crucial for breaking down the organic matrix at the transcriptional [27, 28] and at the paracrine levels [29] .
This study focuses on the role of S100A4 in the regulation of bone mass in vivo, and on the functional changes of bone remodelling cells related to the absence of S100A4. Using S100A4KO mice and mice in which S100A4 transcription was suppressed by shRNA, we found that a deficiency of S100A4 was associated with increased bone mass formation in trabecular and cortical bone compartments, accompanied by a decrease in the expression of integrins essential for resorptive pit sealing, and of bone resorptive enzymes, such as cathepsins and matrix metalloproteinases.
Material and methods

Mice
S100A4KO mice were generated by a germ-line inactivation of the S100A4 gene (Mts-1) as previously described [30] The clones containing deletion of the S100A4 gene were aggregated with the eight-cell embryos followed by implantation into pseudopregnant mice. Germ-cell transmission was proved by tail biopsy and S100A4KO mice were maintained by intercrossing of littermates. Breeding pairs of S100A4KO and WT mice of congenic A/sn strain were kindly provided by Dr. Mariam Grigorian, Institute of Cancer Biology, Copenhagen, Denmark. The mice were bred and housed in the animal facility of the Department of Rheumatology and Inflammation Research, University of Göteborg, under standard conditions of temperature and light, and were fed laboratory chow and water ad libitum. To assure that the phenotypic differences were not caused by drifting of the strains following long-term parallel breeding S100A4KO and WT mice were intercrossed to generate congenic homozygous, heterozygous and wild-type siblings. All animal studies were approved by the Animal Experimental Board of the University of Göteborg.
In vivo inhibition of S100A4 transcription
Two lentiviral constructs containing two different sequences encoding shRNA targeting S100A4 gene transcripts were prepared by Sigma-Aldrich (St. Louis, MO. MissionTRC, TRCN0000011859 and TRCN0000011860, respectively). shRNA sequences are available on the website www.sigmaaldrich.com. WT mice (8 weeks old, 7 females and 8 males) were treated with a combination of the two types of lentiviral particles, 2 × 10 6 transduction particles in 100 μl/mouse injected intra-peritoneally, once weekly for 5 consecutive weeks. The control groups received the same titre of non-targeting lentiviral particles, Non-Target Control (SHC002H) (n = 8). Inhibition of S100A4 in bone marrow cells was tested by qPCR and by Western blot.
Treatment of mice with MMP inhibitor
WT mice (5 males and 5 females, 5 weeks-old) were orally treated with a broad-spectrum MMP inhibitor PD166793 (Tocris Biosciences, Bristol, UK) in the dose 30 mg/kg/day for 28 day, as previously described [31] . This inhibitor binds to the catalytic site of the enzyme and has high inhibitory activity to MMP2, MMP3 and MMP13, and weak inhibitory activity to MMP1 and MMP9.
Reagents
For flow cytometry analysis following anti-mouse antibodies have been used: RANK (R12-31, Biolegend, San Diego, CA, USA), CD61 (2C9.G2, Becton-Dickinson, Franklin Lakes, NJ, USA), CD62L (MEL-14, BD), CD3 (145-2C11, BD), CD49e (5H10-27, BD), CD49b (HMα2, BD), CD29 (HMb1-1, BD), B220 (RA3-6B2, BD), CD18 (C71/16, BD), as well as rat IgG2β,κ, which served as an isotype control for RANK staining. Monoclonal antibodies conjugated with PE, APC, PB, APC-H7, FITC, eFluor450, PerCp, PeCy7, or biotin, were used. For flow cytometry purposes also streptavidin conjugated with APC (Becton-Dickinson) was utilised. For in vitro osteoclastogenesis, recombinant murine sRANKL and recombinant murine M-CSF were purchased from PeproTech. All culture plates as well as chamber slides were purchased from Nunc.
Serological parameters
Serum levels of markers of bone turnover and immunological markers were assessed in serum samples from experiment termination. Osteocalcin, a bone formation marker, was analysed with a mouse IRMA kit (Immutopics Inc., San Clemente, CA), CTX-I, a collagen type I degradation fragment, was assessed with a Ratlaps ELISA kit (IDS Nordic, Herlev, Denmark). Osteopontin (OPN, DY441), osteoprotegerin (OPG, DY459), RANK-ligand (RANKL, DY462), matrix metalloproteinase 3 (MMP3, MMP300), MMP9 (DY909), IGF-1 (DY791) and soluble L-selectin (CD62L, DY576) were analysed with ELISA duo-sets (RnD Systems, Minneapolis, MN).
Bone marrow isolation and cell analysis
Cells obtained via flushing of the bone marrow cavity of both femoral and tibial bones with PBS, and lysis of erythrocytes with 0.83% NH4Cl in Tris buffer, were used for osteoclastogenesis or flow cytometry.
In vitro osteoclastogenesis
Bone marrow cells were first seeded on cell culture plastic for 3 h to adhere stromal cells. Later non-adherent cells were harvested, counted and cultured in the complete α-MEM supplemented with M-CSF (10 ng/ml) for 48-72 h. Osteoclast differentiation was initiated by the addition of sRANKL (0-100 ng/ml) for different time periods. Bone marrow cells of WT and S100A4KO mice were cultured in the presence of recombinant S100A4 (0-0.01-0.1 ng/ml). Cells were submitted to phenotype analysis by flow cytometry, and to morphological evaluation. For TRAP staining an acid phosphatase kit (Sigma-Aldrich, St Luis, MO, USA) was used. Mature osteoclasts were identified as TRAP-positive multinuclear cells and their number was calculated (Leica DMR microscope with LeicaQWin software, Leica, Heidelberg, Germany). For immunofluorescence, osteoclast cultures were treated as described (24) and subjected to a double staining procedure. In brief, anti-S100A4 antibodies (ab27957, Abcam, Cambridge, UK), or anti-β 3 -integrin antibodies (ab47584, Abcam) was followed by secondary goat-anti-rabbit IgG-AlexaFluor555 antibody (A21428, Life, Paisley, UK). Actin filaments were stained with phallacidin-Bodipy FL (Life). Slides were mounted with Prolong gold antifade reagent containing 4′,6-diamidino-2-phenylindole for nuclear staining (Life). Normal rabbit IgG (Dako, Glostrup, Denmark) was used as negative isotype controls. Images were collected using a confocal microscope (LSM700; Zeiss, Oberkochen, Germany). The background fluorescence level was set with the negative controls and images were analysed using the software provided by Zeiss.
Flow cytometry
Bone marrow cells or cultured cells were resuspended in FACS buffer (containing 1% FCS, 0,1% NaN 3 , 0,5 mM EDTA), and incubated with rat anti-mouse CD16/32 (F c -block, BD Pharmingen) for elimination of non-specific binding of antibodies to F c -receptors. The cells were then incubated with indicated antibodies. Stained cells were analysed using FACSCanto machine and FACSDiva software (BD). All analyses were performed using the FlowJo software (Tree Star Inc., Ashland, OR, USA) and gating was based on appropriate fluorescence minus one controls. Bone marrow leukocytes were retrieved as described before [32] .
Gene expression analysis
Total RNA from bone marrow cells was extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The concentration and quality of the RNA were evaluated with Nanodrop Spectrophotometer (Thermo Scientific, USA) and Experion (Bio-Rad laboratories Inc., USA). 400 ng RNA was used for cDNA synthesis using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time amplification was performed with RT 2 SYBR®
Green qPCR Mastermix (Qiagen) using a ViiA™7 Real-Time PCR System (Life). The RT-PCR reaction was performed using 200 nM of forward and reverse primers, and 4 ng total RNA in a final volume of 25 μl. The expression of the following genes was measured: Csf1, Ctsk, Ctsl, Mmp2, Mmp3, Mmp9, Mmp13, Plau, RANKL, Runx2, LRP5, Itga5, Itgb1, Itgb2, Itgb3, Plaur, S100A4. Expression levels of these genes were normalised to the reference genes, Gapdh and Ppia. The sequences of primers used in real-time PCR are available from SABiosciences (Qiagen) upon request, except for: Mmp2: 5′-CATCGCCCATCATCAAGTT-3′ and 5′-GGGCAGCCATAGAAAGTGTT-3′, Mmp13: 5′-TGATGAAACCTGGACAA GCA-3′ and 5′-CCTGGGTCCTTGGAGTGAT-3′, LRP5: 5′-GCTGCTGCTGGT GCTGTACT-3′ and 5′-CATCCACTAGCCGCACATC-3′. A negative control (no template) reaction was performed for each primer pair tested. A melting curve for each PCR was performed between 60°C and 95°C to ensure that only a single product had been amplified. The results were expressed as the fold change compared with the expression levels in the WT control cells with the ddCq-method.
Peripher quantitative computed tomography (pQCT)
Left femur was subjected to computed tomographic scan using Stratec pQCT XCT Research M software (Norland, Fort Atkinson, WI) at a resolution of 70 μm, as described [33] . Trabecular and cortical volumetric BMC and BMD, bone geometry, and strength strain (moment of inertia and moment of resistance) were assessed. Trabecular bone was determined with a metaphyseal scan, at a point located 3% of the length of the femur from the growth plate, and a density threshold of 280 mg/cm 3 . Cortical BMD was defined with a mid-diaphyseal scan taken 7 mm from the distal end of the femur at density threshold of 710 mg/cm 3 . This mid-diaphyseal scan permitted assessment of cortical BMD, BMC, cortical thickness, cortical area, endocortical and periosteal perimeters, and bone strength.
Microcomputed tomography (micro-CT)
The left femoral bone was scanned and reconstructed into a three-dimensional structure with Skyscan1176 micro-CT (Bruker, Antwerp, Belgium) with a voxel size of 9 μm. The scanning was done at 50 kV/499 mA, with a 0.2 mm aluminium filter. Exposure time was 795 ms. The X-ray projections were obtained at 0.3°intervals with a scanning angular rotation of 180°. The projection images were reconstructed into three-dimensional images using NRECON software (version 1.5.1; Bruker). The reconstructed dataset was segmented by an automated thresholding algorithm and analysed with CT-Analyzer (version 1.7; Bruker). The analysis was performed on a region of interest (ROI) chosen as a 1.4 mm slice starting 2% from the proximal growth plate. The trabecular compartment ROI was obtained by shrinking the total bone volume by 30 voxels from the outside. The parameters measured and calculated were as follows: (1) tissue volume and (2) trabecular volume was calculated by the marching cubes method. The pictures were obtained with the software CT-Vox (Bruker) using the total bone volume ROI.
Histomorphometric analysis
Left femurs were collected, transferred in 70% ethanol and embedded in methylmethacrylate. Longitudinal sections of the undecalcified bone were cut using rotation microtome (Leica) with tungsten carbide blade. The undecalcified sections were stained by a modified MassonGoldner trichrome technique and subjected to static histomorphometry by Pharmatest Service (Turku, Finland). Bone histomorphometric measurements were performed in the distal femur metaphysis using OsteoMeasure histomorphometric system (Osteometrics, Atlanta, version 2.2, USA). Three consecutive fields with the total area of 0.75 mm 2 were measured along the vertical axis of the central metaphysis. Trabecular width and trabecular number were calculated [34] . Sections were used for evaluation of osteoblast and osteoclast number and activity.
Morphology and immunohistochemistry
At the end of experiments, femoral bones were collected and fixed in 4% (w/w) formaldehyde, decalcified with 10% (w/v) EDTA in 0.1 M Tris-buffer (pH 6.95), routinely processed and embedded in paraffin. For immunohistochemistry staining, 4 μm tissue sections were deparaffinised and for osteocalcin staining epitope retrieval by trypsin treatment was performed. Endogenous peroxidase was depleted by incubating with 3% H 2 O 2 followed by an overnight incubation with a titrated amount of primary antibodies to cathepsin K (ab19027, Abcam) or osteocalcin (LS-C17044, LifeSpan Biotechnology, Seattle, WA, USA). Following washing, the sections were incubated with ImmPRESS anti-rabbit IgG (Vector Laboratories Inc., Burlingame, CA). Colour reaction was completed with impact AEC (Vector). Sections were counterstained with hematoxylin. TRAP staining was performed using Naphtol AS-BI phosphate (Fluka N-2250) on deparaffinised tissue sections. Cathepsin K-positive and TRAP-positive cells were enumerated within three consecutive fields in the metaphyseal, diaphyseal, and in the growth plate areas, using a Leica DMR microscope and the LeicaQWin software. Enumeration of nuclei in TRAP positive cells was done along the growth plate of the 4 μ (2 dimensional) femoral sections. Cells with ≥3 nuclei were considered multinuclear.
In vitro migration assay
The migratory capacity of bone marrow cells was tested using the Transwell TM system with a pore size of 3 μm (Corning Inc., Corning, NY, USA) as previously described [35] . In short, bone marrow cells (5 × 10 5 /well) were placed in the upper chamber and migrated for 1, 3, and 15 h towards M-CSF (50 ng/ml) or 0.1% BSA-PBS dilution buffer as negative control added in the lower chamber. To exclude chemokinesis, M-CSF (50 ng/ml) was included in a set of wells in both lower and upper chambers. Migrated cells were collected from the lower chamber and subjected to phenotype analyses by flow cytometry as described above.
Statistical analysis
Values are reported as mean ± SD or median [IQR] . Comparisons between groups were performed using the paired t-test or MannWhitney U test. The proportion of multinuclear TRAP positive cells was examined with Chi 2 test. A p value of b 0.05 was considered significant.
Results
S100A4-deficient mice have increased bone mass
Peripheral quantitative computer tomography (pQCT) of the femur showed a significantly higher total bone mineral density (BMD) in S100A4KO mice than in age and sex-matched congenic WT mice (Fig. 1A, Supplementary Table 1 ). This elevated BMD was consistently measured in male (mg/mm 3 : 474 ± 11 for S100A4 vs 428 ± 4 for WT, p b 0.001) and in female (mg/mm 3 : 530 ± 11 for S100A4 vs 493 ± 7 for WT, p b 0.05) S100A4KO mice. To exclude parallel breeding as a reason for the observed differences in BMD, S100A4KO and WT mice were crossed. The BMD in 10-week-old F2 offspring was consistently higher in animals with the S100A4KO genotype than in their WT siblings (mean percent difference, 3-17%) (Supplementary Fig. S1A ). The BMD measurements in mice of different ages showed that the bone mass difference between S100A4KO and WT mice was significant at an early age (weeks [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , but decreased by week 25 (Fig. 1B, Supplementary  Table 1) .
To prove the absence of S100A4 to be the key event responsible for the increase in bone mass in S100A4KO mice, WT mice (n = 15, age 8 weeks) were treated intraperitoneally with lentiviral shRNA transduction constructs, which enabled silencing of S100A4 gene transcription and a 54% reduction in S100A4 protein levels in shRNA-treated mice (Fig. 1C, 1D) . BMD assessed by pQCT 5 weeks later, showed a 16% increase in cortical bone mass (p = 0.0007. Fig. 1A ) compared to control WT mice treated with non-targeting constructs, while no difference was seen in trabecular bone mass.
A higher BMD was measured in the trabecular and cortical bone compartments of S100A4KO mice compared to WT (Fig. 1A) . Trabecular density in S100A4KO males was higher and reached 128% of that in the WT counterparts, while cortical parameters were enhanced in females ( Supplementary Fig. S1B ). The cortical compartment in the mid-diaphyseal region of S100A4KO mice was larger compared to The ratio of density S100A4/actin indicates a 50% reduction in S100A4-shRNA treated mice. (E) Left femoral bone of S100A4KO and WT mice (females, 7 weeks old) was subjected to Masson-Goldner trichrome staining and histomorphometry. A representative picture of trabecular bone in the metaphyseal region of S100A4KO and WT mice is shown. Arrows indicate trabeculi (Tr). (F) Trabecular number and trabecular thickness was higher in S100A4KO mice, while space between trabeculi was smaller. (G) Microcomputer tomography of the left femoral bone of S100A4KO and WT mice (females, 9 weeks old) showed an increase in bone content in S100A4KO mice. Consistently, the tissue and trabecular volume was increased in S100A4KO mice. *P b 0.05, **P b 0.01, S100A4KO vs. WT, Mann-Whitney test, median [IQR], n = 7-10 mice/group.
WT mice due to a larger periosteal circumference and to a consequently increased cortical area (mm 3 : 0.86 ± 0.02 vs 0.78 ± 0.01, p b 0.01; Fig. 1A ). Bone strength predicted from geometric measures obtained with pQCT was greater in S100A4KO mice than in WT mice with respect to bending (moment of inertia, p = 0.013) and twisting (moment of resistance, p = 0.025) (Fig. 2F) . Histomorphometric analysis of the undecalcified trabecular bone in the femoral metaphyseal region revealed a higher number of trabecules in S100A4KO mice (Fig. 1E, F) . Those trabecules were thicker and reduced significantly the inter-trabecular space. These findings were supported by a micro-CT analysis of the distal femoral metaphysis. Three-dimensional trabecular architecture in S100A4KO and WT mice showed higher tissue volume and higher trabecular volume in S100A4KO mice (Fig. 1G) , which are consistent with the osteopetrotic phenotype of S100A4KO mice.
Low protease levels in the osteoclast resorptive pit lead to a poor osteolytic capacity in S100A4-deficient mice
Histomorphometric analysis of the undecalcified trabecular bone following Masson-Goldner staining showed a high number of trabecular-adherent osteoblasts in S100A4KO mice than in WT mice (p = 0.003) ( Fig. 2A) , while the number of osteoclasts was similar in WT and S100A4KO mice. Immunostaining of the decalcified femoral bone revealed comparable numbers of osteocalcin + osteoblasts in S100A4KO and WT mice (Fig. 2B) , while a significantly lower number of TRAP+ cells was found in the growth plate and in the trabecular bone of S100A4KO mice (Fig. 2C) . Additionally, TRAP+ cells of S100A4KO mice were infrequently multinuclear; analysis of femoral bone sections showed that only 6% of the S100A4KO TRAP+ cells had ≥3 nuclei, compared to 42% of the WT TRAP+ cells (p b 0.001) (Fig 2B 3 ) . Staining for cathepsin K, the main cysteine protease of the osteoclast resorptive pit, revealed significant low number of cathepsin K+ cells in S100A4KO mice compared to WT mice (Fig. 2D) . The difference in the number of cathepsin K+ cells was pronounced in the growth plate region and along cortical bone. These morphological findings were consistent with lower mRNA levels for the bone-resorptive proteins cathepsin K (Fig. 2E 1 ) , and metalloproteinase MMP13 measured in the bone marrow of S100A4KO mice (Fig. 2E 2 ) .
Low levels of MMPs do not account for the increased bone mass in S100A4 deficient mice
The expression of MMPs showed a significant variation in the bone marrow of S100A4KO mice; MMP13 mRNA was low, while MMP3 and MMP9 were high (Fig. 2E 2 ) . The serum levels of MMP3 and MMP9 were strikingly low in S100A4KO mice (Fig. 2F , Supplementary Table 2 ). Induction of MMPs is attributed to the extracellular functions of S100A4 [36] . The ability of S100A4KO cells to respond to stimulation with recombinant S100A4 was tested in bone marrow cultures. Stimulation with recombinant S100A4 induced similar and dose-dependent induction of MMP2 and MMP9 mRNA in WT and S100A4KO bone marrow cells (not shown).
To further study the potential impact of low MMP levels in bone homeostasis of S100A4KO mice, WT mice were orally treated for 28 days with a synthetic MMP inhibitor (MMPi) with high affinity for active MMP2, MMP3, and MMP13, after which the animals were sacrificed and BMD was measured. MMPi-treated animals showed a 16% lower cortical content as well as a lower estimated functional resistance to bending (moment of inertia, p b 0.001) and twisting (moment of resistance, p b 0.001) compared to PBS-treated controls (Fig. 2F) . The changes in bone mass of MMPi-treated mice were remarkably different from the high cortical content observed in S100A4KO mice, which indicated that low MMP levels were unlikely to be accountable for the abnormal bone phenotype in S100A4KO mice.
Persistent osteoclast formation predicts increased bone turnover in S100A4-deficient mice
Several levels of evidence indicated that there is increased bone metabolism in S100A4KO mice. These mice show signs of osteoblast activation, with 2.25-folds higher expression of LRP5 (p = 0.004) and Runx2 (ns) in the bone marrow (Fig. 3A) and higher serum levels of the bone matrix protein OC (ng/mL: 118 ± 12 vs 166 ± 19, p = 0.003) compared to WT mice (Supplementary Table 2 ). Stimulation of bone marrow cells with recombinant S100A4 revealed that the expression of LRP5 belongs to the intracellular functions of S100A4 and could not be substituted by extracellular stimulation (Fig. 3A) . By contrast, expression levels of Runx2 and OC were affected by extracellular S100A4, with Runx2 induced selectively in S100A4KO cells, while OC expression was suppressed by recombinant S100A4 independently of the S100A4-status of stimulated cells. Additionally, S100A4KO mice had increased osteoclast activation capacity due to lower serum levels of OPG (p = 0.02) and a relatively high availability of the free RANK-ligand (Supplementary Table 2 ).
The in vitro differentiation of osteoclasts from bone marrow progenitors resulted in the formation of high numbers of TRAP + cells in S100A4KO cultures compared to WT (Fig. 3B) . Morphologically, S100A4KO osteoclasts were smaller, rounder, and developed fewer cytoplasmic protrusions than TRAP+ osteoclasts in WT mice (Fig. 3C 1,2 ) . Additionally, confocal microscopy findings supported these morphological differences, showing that S100A4KO osteoclasts had few cytoplasmic protrusions and low expression of surface CD61 (Fig 3C 3,4 ) . Flow cytometry of the bone marrow cells cultured in M-CSF rich media showed that 72% of osteoclast precursors in S100A4KO mice gained a CD61+RANK+ phenotype compared to 43-56% in WT mice (Fig. 3D,  upper line) . Also, the intensity of CD61 expression was 20% lower on the surface of S100A4KO compared to WT osteoclast precursors (p = 0.001. Fig. 3D ). The S100A4KO osteoclasts were produced by fusion of 1-3 precursors and contained few nuclei (Fig 3C 2,4 ) , while WT osteoclasts were bigger in size (Fig. 3C 1,3 ) and were multinuclear. The presence of these paucinuclear osteoclasts in vitro were similar to the observations done in vivo that osteoclasts along the trabecular structures in metaphysis of S100A4KO mice rarely had ≥3 nuclear number (Fig. 2B 3 ) . A relationship between the osteoclast phenotype and the expression of S100A4 was shown by silencing of the S100A4 gene in WT cells with lentiviral shRNA. S100A4shRNA-treated cells gained the RANK+CD61+ phenotype and showed low CD61 surface expression (Fig. 3D, lower line) . The S100A4shRNA-treated cells were rounder and formed less cytoplasmic protrusions (Fig. 3C 6 ) compared to cells treated with NT-RNA (Fig. 3C 5 ) .
Low surface integrin expression induces morphological changes and insufficient matrix attachment in S100A4-deficient osteoclasts
Integrins are crucial for the survival, motility and adhesion of osteoclasts (Fig. 3C 3,4 ) . They are also an important component of podosomes in the sealing zone of these cells, as they are responsible for resorptive pit separation [37] . Flow cytometry showed that the expression of integrins was lower in the freshly isolated bone marrow monocytic cells of S100A4KO mice (Fig. 3E) . A particularly prominent difference was seen in surface expression of the α 2 -and α 5 -chains (which were N2.5-fold lower in S100A4KO cells than in WT cells) and the β 3 -and β 2 -integrins. This low surface expression of integrins opposed the 6-40-fold higher mRNA levels of these integrins in the bone marrow of S100A4KO mice compared to WT mice (Fig. 3E) , which made the actual difference in integrin expression of S100A4KO and WT bone marrow cells even bigger. Stimulation of bone marrow cells with Fig. 2 . S100A4-deficiency results in low osteoclast formation in vivo. (A 1 ) Sections of undemineralised femoral bone of S100A4KO and WT mice were subjected to Masson-Goldner trichrome (MGT) staining. Osteoclast (OC) stains intensive red and osteoblast (OB) are pale red, indicated by arrowheads. (A 2 ) Osteoclasts and osteoblasts within the trabecular area were enumerated along the trabecular perimeter. Immunomorphological staining of the methaphyseal region of trabecular bone shows low number of osteocalcin + osteoblasts (B), TRAP+ (C) and cathepsin K+ (CtsK) osteoclasts (D) in S100A4KO and WT mice. Osteoblasts, TRAP+ and cathepsin K+ cells (stained red, indicated by arrowheads) were enumerated in trabecular bone and in the growth plate of S100A4KO and WT mice. The bar on the microphotographs corresponds to 100 μm. The nuclei within each TRAP+ cell were counted and showed that S100A4KO osteoclasts seldom contained ≥3 nuclei (B 3 ). mRNA expression of cathepsin K and cathepsin L (E 1 ) and MMP3, MMP9 and MMP13 (E 2 ) was measured in bone marrow cells of WT and S100A4KO mice. Expression is normalised to Gapdh and Ppia reference genes. (F) WT mice were treated with a non-selective MMP inhibitor PD166793 (MMPi, 30 mg/kg/d for 28 days). Total BMD and the bone strength parameters, predicted moment of inertia and moment of resistance, are shown in MMPi-treated and in control WT mice treated with vehicle (Veh). Low levels of serum MMP3 and MMP9 are measured in S100A4KO and not in MMPi-treated WT mice. (*P b 0.05, **P b 0.001, ***P b 0.0001, Mann-Whitney test, S100A4KO vs. WT; box-plots are median [IQR] and range, n = 10-12 mice/group). recombinant S100A4 resulted in a significant increase in α2, α5 and β3-integrin levels, both in WT and in S100A4KO cultures (Fig. 3F) . These integrin chains comprise essential subunits for the receptors of collagen type I (α 2 β 1 ), fibronectin (α 5 β 1 ), and vitronectin (α v β 3 ), and their deficiency provides a structural explanation for the defective adhesion of S100A4KO osteoclasts to these matrix proteins. To study whether the low surface expression of integrins has a functional significance, the motility of S100A4KO and WT bone marrow cells was assessed by their migration towards M-CSF. We observed that S100A4KO cells were capable of early migration (1 h), with the number of migratory cells continuing to increase after 15 h, at which point the migratory potential of WT cells decreased (Fig. 3G) . The migration results are consistent with high motility of S100A4 leukocytes and the reduced adhesion capacity of S100A4KO cells.
Discussion
The present study shows that S100A4 protein deficiency is associated with disturbed bone metabolism, the cumulative result of which is excessive bone mass, i.e., osteopetrosis. Indeed, in S100A4KO mice, bone tissue was characterised by an increase in the number and thickness of the trabeculae and in the thickness of lamellar cortical bone. The differences in bone mass were pronounced at an early age and levelled-off after the age of 20 weeks. Selective inhibition of S100A4 gene transcription was also associated with excessive bone mass. A 5-week acute inhibition of S100A4 in mature mice resulted in a significant accumulation of cortical bone in WT mice, which suggests an essential regulatory contribution of S100A4 in the process of bone formation. Histologically, S100A4KO bone showed increased cellularity, with a higher number of trabecular osteoblasts than was found in WT bone. At the cellular level, the high bone mass that developed in S100A4KO mice was consistent with increased osteoblast activity, as evidenced by the higher levels of Runx2 and LRP5 mRNA and the bone matrix proteins, OP and OC. The importance of S100A4 for osteoblast maturation has been reported based on the accumulation of S100A4 in mesenchymal cells in the vicinity of developing bones and of the tooth bud [38] . These observations are supported by reports of high expression of bone sialoprotein and OC in S100A4-deficient cell clones [20, 21] . Downregulation of S100A4 with siRNA was associated with an increase in the number of mineralised nodules in vitro.
In addition to overactivated osteoblasts, S100A4KO mice showed low number of TRAP+ and cathepsin K+ osteoclasts attached to trabecular structures in femoral bone. S100A4-deficient osteoclasts contained low cell nuclei number compared to WT osteoclasts, indicating disturbances in multinucleation. The reduced number of functional osteoclasts in vivo is in contradiction to the amplified formation of RANK+CD61+ preosteoclasts and of small TRAP + cells observed in cultures of S100A4KO mice. The morphology of differentiated S100A4KO osteoclasts in vitro was abnormal, as they exhibited a distorted round shape, poor ability to spread over the surface, few nuclei, and fewer podosomes. These observations were not unexpected based on the current understanding of the role of S100A4 in cell motility and adhesion during tumour metastasis [2] and in bone marrow-derived macrophages [39] . S100A4-deficient macrophages form small and unstable protrusions, which resulted in severely altered chemotaxis in vitro and in a poor mobilisation of macrophages to the inflammation site in an acute thioglycolate-induced model of peritonitis [39] . Poor influx of inflammatory cells in the joints of S100A4KO mice was recently reported in a septic arthritis model [16] . In fact, cell motility is thought to be the primary function controlled by S100A4 through its interaction with cytoskeletal proteins, namely, F-actin, tropomyosin, and non-muscle myosin II [16] . The molecular basis of the high motility and dysfunctional adhesion seen in our S100A4KO experimental model is likely related to the reduced surface expression of α 5 -and β 1 -integrins, as both integrins are vital subunits of the receptors that bind extracellular matrix proteins [40] . Additionally, the expression of integrins is related to cell survival. Inhibition of S100A4 in tumour cell lines through RNA interference results in downregulation of α5 and αv integrin expression at the transcriptional level and promotes apoptosis of detached cells [25] . We observed high integrin gene transcription and a relatively decreased surface expression of the same integrins in bone marrow cells, which may be explained by an increased integrin turnover and/or by suppressed protein translation in the absence of S100A4. Extracellular stimulation with recombinant S100A4 induced similar expression of integrins on the surface of S100A4KO cells and WT cells. This implies functional protein translation and favours dysfunctional upregulation and stabilisation of integrins on the surface of S100A4KO cells.
In addition to the effects on cell motility and adhesion, the expression of β 3 -integrin is required for proper sealing of the osteoclast resorptive pit. Low levels of β3-integrin may, at least in part, explain the poor resorptive capacity of S100A4KO osteoclasts in vivo. Deficiencies in podosome-associated proteins, such as MMPs and cathepsins, are described among the molecular mechanisms resulting in insufficient bone resorption. Extracellular S100A4 stimulates production of MMP13 via its interaction with surface-bound RAGE [8] , and by transcriptional regulation of MMP9 [28] and MMP13 [41] binding the promoter regions of the respective genes. We observed inconsistency between low protein levels of MMP9 and MMP3 and high mRNA levels of MMP9 in S100A4KO mice, while mRNA levels of MMP3 were similar to those of WT mice. This observation together with the discrepancy in mRNA and protein levels of integrins suggests that S100A4 may be important for post-translational stabilisation of these proteins.
The role of MMP deficiency in the development of the excessive bone mass phenotype in S100A4KO mice is uncertain. In studies on MMP knock-out mice, MMP2-deficient animals showed cranio-facial abnormalities and developed osteoporosis [42] . Consistently, mice with targeted mutations to the MMP9 and MMP13 genes exhibited defective endochondral bone development associated with enlarged hypertrophic zones, poorly aligned chondrocyte columns, and progressive lengthening of the growth plate of long bones [29, 43] . Despite multiple deficiencies in MMPs, abnormalities in joint and cartilage development, which are characteristic of double MMP9/MMP13-deficient Fig. 3 . S100A4-deficient osteoclasts show disturbances in cell morphology and phenotype. (A) mRNA expression of LRP5 and Runx2 was measured in bone marrow cells of S100A4KO and WT mice. Expression is normalised to Gapdh and Ppia reference genes. Changes in mRNA expression of Runx2, LRP5 and osteocalcin following stimulation of bone marrow cultures with M-CSF and different concentrations of recombinant S100A4. (B) Osteoclasts derived from bone marrow of WT and S100A4KO mice by culturing in the presence of M-CSF (10 ng/ml) and RANKL (5 or 20 ng/ml) were stained for TRAP and enumerated (C1 2 ). Representative picture of TRAP+ osteoclasts (red) is shown in S100A4KO and WT cultures. S100A4KO osteoclasts (C 2,4 ) are smaller in size and develop few cytoplasmic protrusions compared to WT (C 1,3 ). Confocal microscopy of osteoclast cultures showed smaller adherent surface and few nuclei in S100A4KO cells (C 4 ) compared to WT osteoclasts (C 3 ). Nuclei are stained with DAPI (blue). Expression of β3-integrin (CD61) is shown in red. Actin filaments are stained with phallacidin-Bodipy FL (green). WT bone marrow cells were cultured in the presence of S100A4-shRNA lentiviral construct (C 6,6a ) were smaller in size and had few cytoplasmic protrusions compared to cells cultured with non-targeting RNA construct (C 5,5a ). Confocal microscopy showed accumulation of S100A4 (red) at the leading edge of the cells in the vicinity of actin structures (green) (C 5,5a ). Nuclei are stained with DAPI (blue). (D) Surface expression of RANK and β3-integrin (CD61) were analysed in the bone marrow-derived osteoclast precursors of WT and S100A4KO mice on day 3 with M-CSF, by flow cytometry. WT cultures treated with S100A4-shRNA and non-targeting lentiviral constructs. S100A4KO cultures (upper row) and WT cultures treated with S100A4-shRNA construct (bottom row) had a significantly larger population of RANK+CD61+ osteoclast precursors. Both S100A4-deficient cultures had low intensity of CD61 expression. (E) The mRNA and surface expression of integrins is measured on bone marrow mononuclear cells of S100A4KO and WT mice by flow cytometry. Data are normalised against WT bone marrow cells. (F) Changes of surface integrins on bone marrow cells of S100A4KO and WT mice following stimulation with recombinant S100A4 are normalised to cells cultured in conditional media. (G) Migration of bone marrow cells towards M-CSF (50 ng/ml) was studied in the trans-well system for 1, 3 and 15 h. S100A4KO cell cultures showed prolonged migration capacity. (*P b 0.05, **P b 0.001, ***P b 0.0001, Mann-Whitney test, median [IQR] and range, n = 7-12 mice/group). mice, were not observed in S100A4KO mice. Similarly, WT mice treated with a non-selective synthetic inhibitor of MMP developed increased bone fragility; this phenotype is in clear contrast to the high cortical mass seen in S100A4KO mice in this study.
In naturally developed osteoclasts of S100A4KO mice, the protein levels of MMPs and cathepsin K were lower than in WT mice. S100A4KO mice also had significantly less TRAP + and cahepsin K+ osteoclasts in the growth plate area and along the cortical bone than WT mice. Cathepsin K is the major cysteine protease of the osteoclast resorptive pit as reviewed by Lazner [44] , and is crucial for the breakdown of the collagen network and triple-helical collagens in lysosomes. The critical role of cathepsin K in bone remodelling is supported by the finding that a deficiency in cathepsin K activity leads to an autosomal recessive bone-sclerosing disorder characterised by osteosclerosis and short stature in men [45] . A similar osteopetrotic phenotype is seen in cathepsin-K-deficient mice [46] . In the S100A4KO mice used in this study, cathepsin K activity of trabecular-adherent osteoclasts and bone marrow osteoclast progenitors was lower than that in WT mice. Moreover, the S100A4KO mice exhibited signs of an osteopetrotic phenotype in trabecular and cortical bone, together with shorter femurs. In the absence of cathepsin K, MMPs may be recruited for bone resorption [47] , which in turn requires cathepsin L. Thus S100A4 appears to be a common inducer of proteases as both MMP and cathepsin expression levels were low in S100A4KO mice. Furthermore, since all nuclei of osteoclasts are transcriptionally active [48] , paucinucleation in S100A4KO mice may be an additional mechanism accounting for the low cathepsin K and TRAP levels in S100A4-deficient osteoclasts. The reduced number of functional osteoclasts in vivo is in contradiction to the increased formation of RANK+CD61+ preosteoclasts in cultures of S100A4KO mice. The present study outlines an essential molecular basis for this discrepancy, including impaired adhesion capacity and poor multinucleation of S100A4 osteoclasts, as well as the low expression of the proteolytic enzymes cathepsin K, MMP3 and MMP9 to break down the organic matrix.
In conclusion, we have shown that S100A4 deficiency in mice is associated with a generalised increase in bone mass, resulting from a low number of osteoclasts and activation of osteoblasts. The molecular mechanisms responsible for the dysfunctional osteoclasts include the reduced expression of integrins, which contribute to the formation of receptors for extracellular matrix proteins within the sealing zone of the resorptive pit of osteoclasts, and the low expression of cathepsin K, which is required for the cleavage of the triple helical structure of mineralised collagen. Taken together, our results are consistent with the role of S100A4 as a negative regulator of bone metabolism. The overexpression of S100A4 protein, which occurs in RA and other inflammation-driven diseases, may be responsible for the excessive bone turnover and osteoporosis characteristic of these conditions. Supplementary data to this article can be found online at http:// dx.doi.org/10.1016/j.bbamcr.2013.06.020.
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